Chiranjeevee Ramanathan Mbbs Saravanan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Chiranjeevee Ramanathan Mbbs Saravanan has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
- Nanditha Karra
Internal Medicine, Osmania Medical College, Hyderabad, India
3 shared publications - Omniat Amir Hussin
Internal Medicine, Manhal University, Khartoum, Sudan
3 shared publications - Arvind Dinesh
Internal Medicine, Kempegowda Institute of Medical Sciences, Bangalore, India
2 shared publications - Jobby John
Cardiology, Dr. Somervell Memorial CSI Medical College and Hospital Karakonam, Trivandrum, India
2 shared publications - Singam Mbbs Shashank
Internal Medicine, Shadan Institute of Medical Sciences, Hyderabad, India
2 shared publications - Akanksha Singh
Department of Internal Medicine, Washington University of Health and Science, San Pedro, Belize
1 shared publication
Latest Publications
- Open Access
- 10 September 2026
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (10) , 6576-6584
Therapeutic efficacy and safety of newly approved FDA drug levoketoconazole in cushing syndrome: a systematic review
Background: Cushing syndrome is a severe endocrinopathy due to chronic hypercortisolism with etiology that includes the administration of exogenous glucocorticoids, pituitary adenomas, ectopic ACTH-producing tumors, and adrenal tumors. Expressed as central obesity, hypertension, glucose intolerance, and psychiatric symptoms, it greatly affects the QoL and has a high association with morbidity and mortality. Aim: This systematic review summarizes data from clinical trials to compare the effectiveness and safety of a newly approved drug, levoketoconazole, for the treatment of Cushing syndrome. Methodology: An extensive search was conducted in PubMed, Google Scholar, and the Cochrane Library for terms related to the effectiveness and safety of levoketoconazole in Cushing syndrome. Selected studies included phase 2 and phase 3 interventional trials enrolling adult patients (≥18 years) with confirmed endogenous Cushing syndrome (ECS). Outcomes of interest included mean urinary free cortisol (mUFC), clinical signs and symptoms, quality of life measures, and adverse events. Risk of bias was assessed using the Cochrane Collaboration Risk of Bias Tool. Results: Six interventional studies were included. In the SONICS phase 3 trial, 62% of patients achieved normalization of mUFC at the end of the 6-month maintenance phase, with sustained biochemical and clinical benefits during extended evaluation. During the randomized withdrawal phase of the LOGICS trial, loss of mUFC response occurred in 95.5% of patients switched to placebo compared with 40.5% of patients who continued levoketoconazole treatment ( P = 0.0002), demonstrating maintenance of biochemical control with active therapy. Common adverse events included nausea, headache, hypokalemia, and fatigue. Serious drug-related adverse events were uncommon but clinically relevant, including hepatotoxicity, QT prolongation, and adrenal insufficiency. Conclusion: Levoketoconazole significantly lowers cortisol levels and alleviates clinical manifestations in patients with Cushing syndrome with reasonable safety. There is a need to perform a periodic checkup of the liver function and adrenal insufficiency. Additional long-term research is needed to strengthen its place in treatment plans.
- 10 September 2026
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (10) , 6576-6584
Open AccessTherapeutic efficacy and safety of newly approved FDA drug levoketoconazole in cushing syndrome: a systematic review
Background: Cushing syndrome is a severe endocrinopathy due to chronic hypercortisolism with etiology that includes the administration of exogenous glucocorticoids, pituitary adenomas, ectopic ACTH-producing tumors, and adrenal tumors. Expressed as central obesity, hypertension, glucose intolerance, and psychiatric symptoms, it greatly affects the QoL and has a high association with morbidity and mortality. Aim: This systematic review summarizes data from clinical trials to compare the effectiveness and safety of a newly approved drug, levoketoconazole, for the treatment of Cushing syndrome. Methodology: An extensive search was conducted in PubMed, Google Scholar, and the Cochrane Library for terms related to the effectiveness and safety of levoketoconazole in Cushing syndrome. Selected studies included phase 2 and phase 3 interventional trials enrolling adult patients (≥18 years) with confirmed endogenous Cushing syndrome (ECS). Outcomes of interest included mean urinary free cortisol (mUFC), clinical signs and symptoms, quality of life measures, and adverse events. Risk of bias was assessed using the Cochrane Collaboration Risk of Bias Tool. Results: Six interventional studies were included. In the SONICS phase 3 trial, 62% of patients achieved normalization of mUFC at the end of the 6-month maintenance phase, with sustained biochemical and clinical benefits during extended evaluation. During the randomized withdrawal phase of the LOGICS trial, loss of mUFC response occurred in 95.5% of patients switched to placebo compared with 40.5% of patients who continued levoketoconazole treatment ( P = 0.0002), demonstrating maintenance of biochemical control with active therapy. Common adverse events included nausea, headache, hypokalemia, and fatigue. Serious drug-related adverse events were uncommon but clinically relevant, including hepatotoxicity, QT prolongation, and adrenal insufficiency. Conclusion: Levoketoconazole significantly lowers cortisol levels and alleviates clinical manifestations in patients with Cushing syndrome with reasonable safety. There is a need to perform a periodic checkup of the liver function and adrenal insufficiency. Additional long-term research is needed to strengthen its place in treatment plans.
- Open Access
- 27 February 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (9) , e47711
Smoking and alcohol consumption as risk factors for colonic diverticulosis and its complications: Systematic review and meta-analysis
Background: Colonic diverticulosis (CD) is a prevalent condition marked by small pouches (diverticula) in the colon wall, particularly in those over 50. Many studies have investigated various risk factors, but the relationship between smoking, alcohol consumption, and CD remains to be decided. This meta-analysis analyses the association between these lifestyle factors and the risk of CD and its complications. Methods: A comprehensive literature search was conducted using PubMed, Embase, and Google Scholar to find relevant studies. Inclusion criteria were based on predefined eligibility standards, focusing on observational studies reporting smoking, alcohol consumption, and CD. Using random effect models, Mantel–Haenszel odds ratios and associated 95% confidence intervals were produced to report the overall effect size. Statistical significance was set at P < .05. Egger’s regression test and Begg–Mazumdar’s rank test were used to assess publication bias. The quality of the included studies was assessed using the Newcastle–Ottawa Scale. Results: Sixty-two studies encompassing 5,66,903 patients were included finally, where the mean age was 73.8 years, and 44.53% were female. Smoking increased the risk of CD (odds ratio [OR]: 1.36, 95% confidence interval [CI]: 1.24–1.48), diverticulitis (OR: 1.59, 95% CI: 1.01–2.51), and diverticular bleeding (OR: 1.51, 95% CI: 1.13–2.02). Ex-smokers also showed a higher risk of CD compared to nonsmokers (OR: 1.31, 95% CI: 1.08–1.59). Alcohol consumption was associated with an increased risk of CD (OR: 1.41, 95% CI: 1.09–1.82). However, no association was found between alcohol consumption and diverticular bleeding (OR: 1.15, 95% CI: 0.77–1.71) or diverticulitis (OR: 1.36, 95% CI: 0.98–1.88). No publication bias was clear in the analysis. Conclusion: This meta-analysis suggests an association between smoking, alcohol consumption, and increased risk of CD. Smoking is associated with an increased risk of CD and diverticular bleeding. The relationship between alcohol consumption and diverticular disease requires further investigation. Future research should explore the mechanisms by which these factors influence the development of CD to understand and inform public health recommendations.
- 27 February 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (9) , e47711
Open AccessSmoking and alcohol consumption as risk factors for colonic diverticulosis and its complications: Systematic review and meta-analysis
Background: Colonic diverticulosis (CD) is a prevalent condition marked by small pouches (diverticula) in the colon wall, particularly in those over 50. Many studies have investigated various risk factors, but the relationship between smoking, alcohol consumption, and CD remains to be decided. This meta-analysis analyses the association between these lifestyle factors and the risk of CD and its complications. Methods: A comprehensive literature search was conducted using PubMed, Embase, and Google Scholar to find relevant studies. Inclusion criteria were based on predefined eligibility standards, focusing on observational studies reporting smoking, alcohol consumption, and CD. Using random effect models, Mantel–Haenszel odds ratios and associated 95% confidence intervals were produced to report the overall effect size. Statistical significance was set at P < .05. Egger’s regression test and Begg–Mazumdar’s rank test were used to assess publication bias. The quality of the included studies was assessed using the Newcastle–Ottawa Scale. Results: Sixty-two studies encompassing 5,66,903 patients were included finally, where the mean age was 73.8 years, and 44.53% were female. Smoking increased the risk of CD (odds ratio [OR]: 1.36, 95% confidence interval [CI]: 1.24–1.48), diverticulitis (OR: 1.59, 95% CI: 1.01–2.51), and diverticular bleeding (OR: 1.51, 95% CI: 1.13–2.02). Ex-smokers also showed a higher risk of CD compared to nonsmokers (OR: 1.31, 95% CI: 1.08–1.59). Alcohol consumption was associated with an increased risk of CD (OR: 1.41, 95% CI: 1.09–1.82). However, no association was found between alcohol consumption and diverticular bleeding (OR: 1.15, 95% CI: 0.77–1.71) or diverticulitis (OR: 1.36, 95% CI: 0.98–1.88). No publication bias was clear in the analysis. Conclusion: This meta-analysis suggests an association between smoking, alcohol consumption, and increased risk of CD. Smoking is associated with an increased risk of CD and diverticular bleeding. The relationship between alcohol consumption and diverticular disease requires further investigation. Future research should explore the mechanisms by which these factors influence the development of CD to understand and inform public health recommendations.
- Open Access
- 12 August 2025
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 87 (10) , 6684-6693
Left atrial appendage closure versus anticoagulation in the management of atrial fibrillation: a systematic review, meta-analysis, and meta-regression analysis
Background: Left atrial appendage closure (LACC) is a nonpharmacological option for individuals with atrial fibrillation (AF). LAAC procedure is characterized by its minimally invasive nature and is considered an alternative to anticoagulants that were usually the first line of treatment for patients at risk for blood clotting. Methods: A literature search of three databases was conducted and relevant randomized controlled trials (RCTs) were selected. A meta-analysis was performed using a random effect model to calculate risk ratios with 95% confidence intervals, and only the articles with the longest follow-up were included in the meta-regression analysis. Bias was assessed using standard methodologies. We included RCTs involving adult patients with AF that compared LAAC with oral anticoagulation therapy. Non-randomized studies, case series, animal studies, and non-English publications were excluded. Results: We included three studies with a 1516 sample size. All three trials investigated the composite hemorrhagic stroke, all-cause mortality, and non-procedural major bleeding as primary outcomes in addition to the risk of systematic embolism, ischemic stroke, and all major bleeding. Compared to anticoagulation medical therapy, the LAAC device showed a statistically significant reduction in the risk of the composite primary outcome, cardiovascular (CV) death, all-cause deaths, and nonprocedural bleed. When compared to medical management, there was no statistically significant difference in the risk of systemic embolism and all-stroke in the LAAC device group. The age had no significant impact on the primary efficacy outcome using the Meta-regression analysis. Conclusion: LAAC has comparable efficacy in preventing strokes. The risk of CV death, all-cause deaths, and nonprocedural relevant bleeding, all of which are associated with the composite primary outcome is lower in the LAAC group versus the oral anticoagulation therapy and can have even greater efficacy with a longer follow-up period.
- 12 August 2025
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 87 (10) , 6684-6693
Open AccessLeft atrial appendage closure versus anticoagulation in the management of atrial fibrillation: a systematic review, meta-analysis, and meta-regression analysis
Background: Left atrial appendage closure (LACC) is a nonpharmacological option for individuals with atrial fibrillation (AF). LAAC procedure is characterized by its minimally invasive nature and is considered an alternative to anticoagulants that were usually the first line of treatment for patients at risk for blood clotting. Methods: A literature search of three databases was conducted and relevant randomized controlled trials (RCTs) were selected. A meta-analysis was performed using a random effect model to calculate risk ratios with 95% confidence intervals, and only the articles with the longest follow-up were included in the meta-regression analysis. Bias was assessed using standard methodologies. We included RCTs involving adult patients with AF that compared LAAC with oral anticoagulation therapy. Non-randomized studies, case series, animal studies, and non-English publications were excluded. Results: We included three studies with a 1516 sample size. All three trials investigated the composite hemorrhagic stroke, all-cause mortality, and non-procedural major bleeding as primary outcomes in addition to the risk of systematic embolism, ischemic stroke, and all major bleeding. Compared to anticoagulation medical therapy, the LAAC device showed a statistically significant reduction in the risk of the composite primary outcome, cardiovascular (CV) death, all-cause deaths, and nonprocedural bleed. When compared to medical management, there was no statistically significant difference in the risk of systemic embolism and all-stroke in the LAAC device group. The age had no significant impact on the primary efficacy outcome using the Meta-regression analysis. Conclusion: LAAC has comparable efficacy in preventing strokes. The risk of CV death, all-cause deaths, and nonprocedural relevant bleeding, all of which are associated with the composite primary outcome is lower in the LAAC group versus the oral anticoagulation therapy and can have even greater efficacy with a longer follow-up period.
- Open Access
- 25 July 2025
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 87 (9) , 5936-5944
Poor sleep quality (PSQ) prevalence in patients with functional dyspepsia (FD): a systematic review and meta-analysis
Background: Functional dyspepsia (FD), a disease of the gastroduodenal tract, is one of the functional gastrointestinal disorders (FGID) characterized by postprandial fullness and epigastric pain not attributed to any underlying organic diseases. Sleep quality refers to individuals’ satisfaction with their overall sleep, including sleep initiation, maintenance, duration, and feeling refreshed upon waking. Despite frequent associations between sleep disorders and FGID, comprehensive data on poor sleep quality (PSQ) in FD patients is lacking. Therefore, this study was conducted to investigate the occurrence of PSQ in patients with PSQ. Methods: PubMed, Scopus, and Web of Science were systematically searched to identify relevant literature. All studies reporting PSQ prevalence in FD patients or sufficient data to calculate it were included. Pooled prevalence was calculated for all studies, and an odds ratio was determined for studies with a healthy control group. Meta-regression and subgroup analyses assessed the moderating effects of different variables. Publication bias was examined using funnel plots and Egger’s test p-value. The work has been reported in line with AMSTAR (Assessing the methodological quality of systematic reviews) Guidelines. Results: To the best of our knowledge, this is the first study that pooled the estimate of prevalence of patients with FD with PSQ. Based on 2138 FD patients, the pooled prevalence of poor sleep quality is 57.2% (95% CI: 37%–75.2%), I 2 = 98.4%. The asymmetric funnel plot and Egger’s test P-value indicated a significant publication bias for the pooled prevalence estimate. FD patients are at higher risk for poor sleep, with an odds ratio of 2.39 (95% CI: 1.86–3.06), I 2 = 1.73%. Conclusion: Poor sleep is highly prevalent among FD patients, who are more susceptible to poor sleep than healthy individuals. The findings of the study should be interpreted with caution owing to the high heterogeneity and the publication bias observed for the pooled prevalence. Future research should standardize diagnostic parameters and investigate other confounding factors like anxiety and depression to achieve more accurate estimates.
- 25 July 2025
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 87 (9) , 5936-5944
Open AccessPoor sleep quality (PSQ) prevalence in patients with functional dyspepsia (FD): a systematic review and meta-analysis
Background: Functional dyspepsia (FD), a disease of the gastroduodenal tract, is one of the functional gastrointestinal disorders (FGID) characterized by postprandial fullness and epigastric pain not attributed to any underlying organic diseases. Sleep quality refers to individuals’ satisfaction with their overall sleep, including sleep initiation, maintenance, duration, and feeling refreshed upon waking. Despite frequent associations between sleep disorders and FGID, comprehensive data on poor sleep quality (PSQ) in FD patients is lacking. Therefore, this study was conducted to investigate the occurrence of PSQ in patients with PSQ. Methods: PubMed, Scopus, and Web of Science were systematically searched to identify relevant literature. All studies reporting PSQ prevalence in FD patients or sufficient data to calculate it were included. Pooled prevalence was calculated for all studies, and an odds ratio was determined for studies with a healthy control group. Meta-regression and subgroup analyses assessed the moderating effects of different variables. Publication bias was examined using funnel plots and Egger’s test p-value. The work has been reported in line with AMSTAR (Assessing the methodological quality of systematic reviews) Guidelines. Results: To the best of our knowledge, this is the first study that pooled the estimate of prevalence of patients with FD with PSQ. Based on 2138 FD patients, the pooled prevalence of poor sleep quality is 57.2% (95% CI: 37%–75.2%), I 2 = 98.4%. The asymmetric funnel plot and Egger’s test P-value indicated a significant publication bias for the pooled prevalence estimate. FD patients are at higher risk for poor sleep, with an odds ratio of 2.39 (95% CI: 1.86–3.06), I 2 = 1.73%. Conclusion: Poor sleep is highly prevalent among FD patients, who are more susceptible to poor sleep than healthy individuals. The findings of the study should be interpreted with caution owing to the high heterogeneity and the publication bias observed for the pooled prevalence. Future research should standardize diagnostic parameters and investigate other confounding factors like anxiety and depression to achieve more accurate estimates.
- Open Access
- 14 July 2025
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 87 (9) , 6072-6077
Multidisciplinary approach to Klippel–Trenaunay syndrome: a case report
Klippel–Trenaunay syndrome (KTS) is a rare inherited disorder presenting as a triad of capillary malformations (cutaneous hemangiomas), soft tissue hypertrophy, and varicosities. Two out of three signs are enough to make a diagnosis. It is associated with gastrointestinal, hematological, neuro-ophthalmic, dermatological, pulmonary, oro-dental, renal cardiac, and vascular complications. There is no curative treatment for the disease. Complications are currently managed symptomatically and thorough documentation of all signs and symptoms is essential for timely identification and management of potential complications, thereby improving patient outcomes. KTS was diagnosed in a 16-year-old female, with dyspnea and fever associated with hemoptysis and abdominal pain. On physical examination, cutaneous findings and signs of respiratory compromise as well as evidence of vascular disease were observed. After appropriate medical care, the patient was soon discharged from the hospital. Following initial treatment, the patient’s symptoms arbitrarily recurred requiring continued medical management and blood product administration to manage complications resulting from KTS. KTS is a chronic disorder with no cure. Patients with KTS are managed symptomatically and require frequent hospitalizations for the same.
- 14 July 2025
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 87 (9) , 6072-6077
Open AccessMultidisciplinary approach to Klippel–Trenaunay syndrome: a case report
Klippel–Trenaunay syndrome (KTS) is a rare inherited disorder presenting as a triad of capillary malformations (cutaneous hemangiomas), soft tissue hypertrophy, and varicosities. Two out of three signs are enough to make a diagnosis. It is associated with gastrointestinal, hematological, neuro-ophthalmic, dermatological, pulmonary, oro-dental, renal cardiac, and vascular complications. There is no curative treatment for the disease. Complications are currently managed symptomatically and thorough documentation of all signs and symptoms is essential for timely identification and management of potential complications, thereby improving patient outcomes. KTS was diagnosed in a 16-year-old female, with dyspnea and fever associated with hemoptysis and abdominal pain. On physical examination, cutaneous findings and signs of respiratory compromise as well as evidence of vascular disease were observed. After appropriate medical care, the patient was soon discharged from the hospital. Following initial treatment, the patient’s symptoms arbitrarily recurred requiring continued medical management and blood product administration to manage complications resulting from KTS. KTS is a chronic disorder with no cure. Patients with KTS are managed symptomatically and require frequent hospitalizations for the same.